FDA obefazimod coverage for business development, investment, and market access teams
Earlier
Critical impact AnalysisJun 4, 2026
Abivax Ulcerative Colitis Drug Shows Strong Efficacy, But Cases of Cancer Raise Concerns
ulcerative colitis · 5 min
Michael RodriguezHigh impact AnalysisJun 2, 2026
AbiVax falls as safety worries cloud ‘landmark’ immune drug results
FDA · ulcerative colitis · 7 min
Sarah ChenHigh impact AnalysisJun 2, 2026
Obefazimod ABTECT: UC Remission vs Safety Watch
ulcerative colitis · 11 min
Sarah ChenPopular topics
- Drug Approvals 1,128 articles
- Clinical Trials 634 articles
- Regulatory Updates 687 articles
- FDA News 502 articles
- Press Releases 443 articles
- Oncology 443 articles
- Rare Diseases 141 articles
Explore intelligence
- Global markets Cross-region command center
- Company directory Sponsor & marketer profiles
- Drug profiles INN & regulatory status
- Clinical trials hub Stage & therapy filters
- Pipeline programs R&D intelligence
- Patent landscape US & EP IP moats
- Event calendar Congress catalysts
- Regulatory reference Submission types & pathways